MARKET

JAGX

JAGX

Jaguar Health Inc
NASDAQ
2.480
-0.180
-6.77%
Opening 14:09 07/08 EDT
OPEN
2.660
PREV CLOSE
2.660
HIGH
2.660
LOW
2.360
VOLUME
32.57K
TURNOVER
--
52 WEEK HIGH
97.65
52 WEEK LOW
2.120
MARKET CAP
1.79M
P/E (TTM)
-0.0033
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at JAGX last week (0629-0703)?
Weekly Report · 2d ago
Jaguar Health Completes Conversion of Series O Preferred
TipRanks · 07/01 21:01
Jaguar Health completes Series O preferred conversion into common shares at 3.209-to-1 ratio
PUBT · 07/01 20:34
Jaguar Health provides recap of presentations of crofelemer at ESPGHAN
TipRanks · 06/30 13:15
Jaguar Health says pediatric intestinal failure trial data show crofelemer cuts parenteral support needs up to 48%
PUBT · 06/30 13:00
Weekly Report: what happened at JAGX last week (0622-0626)?
Weekly Report · 06/29 10:07
Deal Dispatch: Penske Buys Vox Media's Digital Brands, AbbVie Acquires Apogee Therapeutics For $10.9 Billion, Camp Mystic Bankruptcy
Benzinga · 06/26 17:52
Jaguar Animal Health Converts Series O Preferred to Common
TipRanks · 06/25 13:50
More
About JAGX
Jaguar Health, Inc. is a commercial stage pharmaceuticals company. The Company is developing prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Its marketed drug Mytesi, (crofelemer 125 mg delayed-release tablets), is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Its Canalevia-CA1, crofelemer delayed-release tablets drug, is an oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea in dogs. It has an exclusive distribution agreement for the sale of Gelclair. It is developing a pipeline of prescription drug product candidates to address unmet needs in gastrointestinal health.

Webull offers Jaguar Health Inc stock information, including NASDAQ: JAGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JAGX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JAGX stock methods without spending real money on the virtual paper trading platform.